The US Senate gave their approval to the Food and Drug Administration (FDA), in conjunction with certain pharmaceutical corporations, for a $6.4 billion “agreement fee” in the new Food and Drug Administration Safety and Innovation Act, S. 3187 (FDASI).
The FDASI is part of Obama’s program to use the US government and drug makers together to discover new ways to use old drugs; as well as find new pharmaceutical answers to new diseases.
The focus of this collaboration will identify new uses for drugs that have already been approved by FDA. There may be need for new human trials, putting the general public at a health risk. Engaging in experimental trials to classify specific compounds to be utilized for unintended purposes is highly dangerous.